# Target Validation Report Template

Full report template with all sections, completeness checklist, and section-specific guidance.

---

## Report Template

```markdown
# Target Validation Report: [FULL PROTEIN NAME]

**Generated**: [Date] | **Query**: [Original query] | **Completeness**: [X/14 phases]

---

## Executive Summary

### Target Validation Scorecard

| Dimension | Score | Max |
|-----------|-------|-----|
| Disease Association | [XX] | 30 |
| Druggability | [XX] | 25 |
| Safety Profile | [XX] | 20 |
| Clinical Precedent | [XX] | 15 |
| Validation Evidence | [XX] | 10 |
| **Total** | **[XX]** | **100** |

**Priority Tier**: [Tier 1-4]
**GO/NO-GO Recommendation**: [Recommendation]

### Key Findings

1. [Finding 1 with evidence tier]
2. [Finding 2 with evidence tier]
3. [Finding 3 with evidence tier]

### Critical Risks

- [Risk 1]
- [Risk 2]

---

## Part A: Target Intelligence

---

## 1. Target Identifiers

| Identifier Type | Value | Database |
|-----------------|-------|----------|
| Gene Symbol | [SYMBOL] | HGNC |
| UniProt Accession | [P#####] | UniProtKB |
| Ensembl Gene ID | [ENSG###] | Ensembl |
| Entrez Gene ID | [#####] | NCBI Gene |
| ChEMBL Target ID | [CHEMBL###] | ChEMBL |
| HGNC ID | [HGNC:####] | HGNC |

**Aliases**: [List all known aliases/synonyms]

---

## 2. Basic Information

### 2.1 Protein Description
- **Recommended Name**: [Full protein name]
- **Alternative Names**: [List]
- **Gene Name**: [Symbol] ([Full gene name])
- **Organism**: [Species] (Taxonomy ID: [####])
- **Protein Length**: [###] amino acids
- **Molecular Weight**: [###] kDa
- **Isoforms**: [Number] known isoforms

### 2.2 Protein Function
[Detailed description of protein function - at least 3-4 sentences]

### 2.3 Subcellular Localization
- **Primary Location**: [e.g., Plasma membrane]
- **Additional Locations**: [List]
- **Topology**: [e.g., Single-pass type I membrane protein]

---

## 3. Structural Biology

### 3.1 Experimental Structures (PDB)

| PDB ID | Resolution | Method | Ligand | Description |
|--------|------------|--------|--------|-------------|
| [####] | [#.#Å] | [X-ray/Cryo-EM/NMR] | [Ligand or Apo] | [Brief description] |

**Total PDB Entries**: [###]
**Best Resolution**: [#.#Å] ([PDB ID])
**Structure Coverage**: [Complete/Partial - which domains?]

### 3.2 AlphaFold Prediction
- **Available**: [Yes/No]
- **Confidence**: [High/Medium/Low - pLDDT scores]
- **Model URL**: [AlphaFold DB link]

### 3.3 Domain Architecture

| Domain | Position | InterPro ID | Description |
|--------|----------|-------------|-------------|
| [Domain name] | [Start-End] | [IPR######] | [Function] |

### 3.4 Key Structural Features
- **Active Sites**: [List with positions]
- **Binding Sites**: [List - substrate, cofactor, drug binding]
- **PTM Sites**: [Phosphorylation, glycosylation, etc.]

### 3.5 Structural Druggability Assessment
- **Binding Pockets**: [Identified pockets suitable for small molecules]
- **Allosteric Sites**: [Known or predicted]
- **Antibody Epitopes**: [Surface accessibility for biologics]

---

## 4. Function & Pathways

### 4.1 Gene Ontology Annotations

**Molecular Function (MF)**:
| GO Term | GO ID | Evidence |
|---------|-------|----------|
| [Term] | [GO:#######] | [IDA/IEA/etc.] |

**Biological Process (BP)**:
| GO Term | GO ID | Evidence |
|---------|-------|----------|
| [Term] | [GO:#######] | [IDA/IEA/etc.] |

**Cellular Component (CC)**:
| GO Term | GO ID | Evidence |
|---------|-------|----------|
| [Term] | [GO:#######] | [IDA/IEA/etc.] |

### 4.2 Pathway Involvement

| Pathway | Database | Pathway ID |
|---------|----------|------------|
| [Pathway name] | [Reactome/KEGG/WikiPathways] | [ID] |

### 4.3 Functional Summary
[Paragraph describing the target's role in cellular signaling, disease mechanisms, and biological importance]

---

## 5. Protein-Protein Interactions

### 5.1 Interaction Network Summary
- **Total Interactors (STRING, score >0.7)**: [###]
- **Experimentally Validated (IntAct)**: [###]
- **Complex Membership**: [List complexes]

### 5.2 Top Interacting Partners

| Partner | Score | Interaction Type | Evidence | Biological Context |
|---------|-------|------------------|----------|-------------------|
| [Gene] | [0.###] | [Physical/Functional] | [Experimental/Predicted] | [Context] |

### 5.3 Protein Complexes

| Complex Name | Members | Function |
|--------------|---------|----------|
| [Complex] | [List] | [Function] |

---

## 6. Expression Profile

### 6.1 Tissue Expression (GTEx/HPA)

| Tissue | Expression Level (TPM) | Specificity |
|--------|------------------------|-------------|
| [Tissue] | [###] | [High/Medium/Low] |

**Tissue Specificity Score**: [Score] ([Broadly expressed/Tissue-specific/Tissue-enriched])

### 6.2 Cell Type Expression
[Single-cell data if available]

### 6.3 Disease-Relevant Expression

| Cancer/Disease | Expression Change | Prognostic Value |
|----------------|-------------------|------------------|
| [Disease] | [Up/Down/Unchanged] | [Favorable/Unfavorable/None] |

---

## 7. Genetic Variation & Disease

### 7.1 Genetic Constraint Scores

| Metric | Value | Interpretation |
|--------|-------|----------------|
| pLI | [0.##] | [Highly constrained/Tolerant] |
| LOEUF | [0.##] | [Interpretation] |
| Missense Z-score | [#.##] | [Interpretation] |
| pRec | [0.##] | [Interpretation] |

### 7.2 Disease Associations (Open Targets)

| Disease | Association Score | Evidence Types | EFO ID |
|---------|-------------------|----------------|--------|
| [Disease] | [0.##] | [Genetic/Literature/etc.] | [EFO_#######] |

### 7.3 Pathogenic Variants (ClinVar)

#### Single Nucleotide Variants (SNVs)
| Variant | Clinical Significance | Condition | Review Status |
|---------|----------------------|-----------|---------------|
| [p.XXX###YYY] | [Pathogenic/Likely pathogenic] | [Condition] | [Stars] |

**Total Pathogenic SNVs**: [###]

#### Copy Number Variants (CNVs)
| Type | Region | Clinical Significance | Frequency |
|------|--------|----------------------|-----------|
| [Amplification/Deletion] | [Region] | [Significance] | [Frequency] |

### 7.4 Cancer Mutations (COSMIC/cBioPortal)

| Mutation | Frequency | Cancer Types | Functional Impact |
|----------|-----------|--------------|-------------------|
| [Mutation] | [#%] | [Cancers] | [Activating/Inactivating/Unknown] |

---

## Part B: Validation Assessment

---

## 8. Disease Association Scoring (0-30 pts)

### 8.1 Genetic Evidence (0-10)

| Evidence Type | Points | Source |
|---------------|--------|--------|
| GWAS associations | [X/6] | GWAS Catalog |
| Rare variants | [X/2] | ClinVar |
| Somatic mutations | [X/2] | cBioPortal |
| Constraint scores | [X/3] | gnomAD |

**Genetic Evidence Score**: [X/10]

### 8.2 Literature Evidence (0-10)

| Metric | Value | Points |
|--------|-------|--------|
| Total target+disease publications | [###] | [X/10] |
| Recent 5-year trend | [Increasing/Stable/Declining] | - |

**Literature Evidence Score**: [X/10]

### 8.3 Pathway Evidence (0-10)

| Disease | OpenTargets Score | Points |
|---------|-------------------|--------|
| [Disease] | [0.##] | [X/10] |

**Pathway Evidence Score**: [X/10]

**Total Disease Association Score**: [X/30]

---

## 9. Druggability Assessment (0-25 pts)

### 9.1 Structural Tractability (0-10)

| Structure Source | Quality | Points |
|------------------|---------|--------|
| PDB structures | [Count, best resolution] | [X] |
| AlphaFold | [pLDDT confidence] | [X] |
| Binding pockets | [Number, quality] | [X] |

**Structural Tractability Score**: [X/10]

### 9.2 Chemical Matter (0-10)

| Source | Compound Count | Best Affinity | Points |
|--------|----------------|---------------|--------|
| ChEMBL | [###] | [IC50/Ki] | [X] |
| BindingDB | [###] | [Ki/Kd] | [X] |
| PubChem BioAssay | [###] | [IC50] | [X] |

**Chemical Matter Score**: [X/10]

### 9.3 Target Class Bonus (0-5)

| Target Class | Points | Rationale |
|--------------|--------|-----------|
| [Class] | [X/5] | [Reason] |

### 9.4 Modality-Specific Tractability

| Modality | Tractability | Bucket | Evidence |
|----------|--------------|--------|----------|
| Small Molecule | [✅/⚠️/❌] | [1-10] | [Evidence] |
| Antibody | [✅/⚠️/❌] | [1-10] | [Evidence] |
| PROTAC | [✅/⚠️/❌] | [1-10] | [Evidence] |

**Total Druggability Score**: [X/25]

---

## 10. Safety Deep Analysis (0-20 pts)

### 10.1 Tissue Expression Selectivity (0-5)

| Critical Tissue | Expression Level | Risk Level |
|-----------------|------------------|------------|
| Heart | [High/Med/Low/None] | [Risk] |
| Liver | [High/Med/Low/None] | [Risk] |
| Kidney | [High/Med/Low/None] | [Risk] |
| Brain | [High/Med/Low/None] | [Risk] |
| Bone Marrow | [High/Med/Low/None] | [Risk] |

**Expression Selectivity Score**: [X/5]

### 10.2 Genetic Validation (0-10)

| Model | Phenotype | Viability | Points |
|-------|-----------|-----------|--------|
| Mouse KO (IMPC) | [Phenotype] | [Viable/Lethal] | [X] |
| Human genetics (pLI) | [Value] | [Interpretation] | [X] |

**Genetic Validation Score**: [X/10]

### 10.3 Known Adverse Events (0-5)

| Adverse Event | Frequency | Drug Class | Mechanism |
|---------------|-----------|------------|-----------|
| [Event] | [Common/Uncommon/Rare] | [Class] | [On-target/Off-target] |

**ADR Score**: [X/5]

### 10.4 Safety Liabilities Summary

| Safety Concern | Evidence | Severity | Organ System |
|----------------|----------|----------|--------------|
| [Concern] | [Animal/Human/Both] | [High/Medium/Low] | [System] |

**Total Safety Score**: [X/20]

---

## 11. Clinical Precedent (0-15 pts)

### 11.1 Approved Drugs

| Drug Name | Brand Name | Mechanism | Indication | Approval Year |
|-----------|------------|-----------|------------|---------------|
| [Drug] | [Brand] | [Inhibitor/Agonist/etc.] | [Indication] | [Year] |

### 11.2 Clinical Pipeline

| Drug | Phase | Indication | Trial Count | Status |
|------|-------|------------|-------------|--------|
| [Drug] | [Phase I/II/III] | [Indication] | [###] | [Active/Completed] |

**Total Clinical Trials**: [###]

### 11.3 Clinical Precedent Score

| Stage | Points |
|-------|--------|
| [Highest stage] | [X/15] |

**Total Clinical Precedent Score**: [X/15]

---

## 12. Validation Evidence (0-10 pts)

### 12.1 Functional Studies (0-5)

| Study Type | Result | Evidence Tier | Points |
|------------|--------|---------------|--------|
| CRISPR KO | [Phenotype] | T1/T2 | [X] |
| siRNA | [Phenotype] | T2 | [X] |
| Biochemical | [Result] | T2 | [X] |

**Functional Studies Score**: [X/5]

### 12.2 Disease Models (0-5)

| Model Type | Result | Evidence Tier | Points |
|------------|--------|---------------|--------|
| PDX | [Response] | T1 | [X] |
| GEMM | [Phenotype] | T2 | [X] |
| Cell line | [Result] | T3 | [X] |

**Disease Models Score**: [X/5]

**Total Validation Evidence Score**: [X/10]

---

## 13. Validation Scorecard

### Composite Score Summary

| Dimension | Score | Max | Percentage |
|-----------|-------|-----|------------|
| Disease Association | [XX] | 30 | [XX%] |
| Druggability | [XX] | 25 | [XX%] |
| Safety Profile | [XX] | 20 | [XX%] |
| Clinical Precedent | [XX] | 15 | [XX%] |
| Validation Evidence | [XX] | 10 | [XX%] |
| **Total** | **[XX]** | **100** | **[XX%]** |

### Priority Tier Assignment

**Tier**: [1-4]
**Recommendation**: [GO/CONDITIONAL GO/CAUTION/NO-GO]

### Modality-Specific Assessment

| Modality | Adjusted Score | Tier | Notes |
|----------|---------------|------|-------|
| Small Molecule | [XX] | [Tier] | [Notes] |
| Antibody | [XX] | [Tier] | [Notes] |
| PROTAC | [XX] | [Tier] | [Notes] |

---

## Part C: Synthesis & Recommendations

---

## 14. Validation Roadmap

### Recommended Validation Experiments

| Priority | Experiment | Rationale | Expected Timeline |
|----------|------------|-----------|-------------------|
| HIGH | [Experiment] | [Why needed] | [Timeline] |
| MEDIUM | [Experiment] | [Why needed] | [Timeline] |
| LOW | [Experiment] | [Why needed] | [Timeline] |

### Data Gaps to Address

| Gap | Recommended Action | Priority |
|-----|-------------------|----------|
| [Gap] | [Action] | [Priority] |

---

## 15. Tool Compounds for Testing

### Recommended Tool Compounds

| Compound | Affinity | Selectivity | Source | Recommended Use |
|----------|----------|-------------|--------|-----------------|
| [Compound] | [IC50/Ki] | [Selectivity profile] | [ChEMBL/SGC] | [Use case] |

### Chemical Probes

| Probe | Selectivity | Use | Source |
|-------|-------------|-----|--------|
| [Probe] | [Selective/Broad] | [Recommended use] | [SGC/etc.] |

---

## 16. Biomarker Strategy

### Predictive Biomarkers

| Biomarker | Type | Assay | Clinical Utility |
|-----------|------|-------|------------------|
| [Biomarker] | [Genomic/Protein/etc.] | [Assay type] | [Utility] |

### Pharmacodynamic Markers

| Marker | Readout | Sample Type | Timepoint |
|--------|---------|-------------|-----------|
| [Marker] | [Readout] | [Sample] | [Timepoint] |

---

## 17. Key Risks & Mitigations

### Risk Assessment

| Risk Category | Risk | Probability | Impact | Mitigation Strategy |
|---------------|------|-------------|--------|---------------------|
| Safety | [Risk] | [High/Med/Low] | [High/Med/Low] | [Mitigation] |
| Efficacy | [Risk] | [High/Med/Low] | [High/Med/Low] | [Mitigation] |
| Competition | [Risk] | [High/Med/Low] | [High/Med/Low] | [Mitigation] |

### Key Strengths

1. [Strength 1]
2. [Strength 2]
3. [Strength 3]

### Key Challenges

1. [Challenge 1]
2. [Challenge 2]
3. [Challenge 3]

---

## Appendices

---

## Appendix A: Data Sources & Methodology

### Databases Queried

| Database | Section(s) | Queries | Status |
|----------|------------|---------|--------|
| UniProtKB | 1, 2, 3 | [accession] | ✅ Success |
| RCSB PDB | 3 | [PDB IDs] | ✅ Success |
| AlphaFold DB | 3 | [accession] | ✅ Success |
| Open Targets | 7, 8, 9, 10 | [ensembl_id] | ✅ Success |
| GTEx | 6 | [gencode_id] | ✅ Success |
| gnomAD | 7 | [gene_symbol] | ✅ Success |
| ChEMBL | 9 | [target_chembl_id] | ✅ Success |

### Tools Used by Phase

| Phase | Tools Used |
|-------|------------|
| 0. Disambiguation | `MyGene_query_genes`, `UniProt_id_mapping`, `ensembl_lookup_gene` |
| 1. OT Foundation | `OpenTargets_get_diseases_phenotypes_by_target_ensemblId`, etc. |
| ... | ... |

---

## Appendix B: Completeness Checklist

- [ ] All identifiers resolved (UniProt, Ensembl, Entrez, ChEMBL)
- [ ] PDB structures listed (if available)
- [ ] All 4 constraint scores reported
- [ ] Top 10 disease associations listed
- [ ] All approved drugs listed
- [ ] Safety concerns documented
- [ ] Validation scorecard complete
- [ ] All phases executed

---

## Appendix C: Data Gaps & Limitations

| Section | Expected Data | Actual | Reason | Alternative |
|---------|---------------|--------|--------|-------------|
| [Section] | [Expected] | [Actual] | [Reason] | [Alternative] |

---

## Appendix D: Structured Data Export (JSON)

```json
{
  "metadata": {
    "target": "[SYMBOL]",
    "uniprot_id": "[P#####]",
    "ensembl_id": "[ENSG###]",
    "report_date": "[YYYY-MM-DD]"
  },
  "validation_score": {
    "total": [XX],
    "tier": [1-4],
    "recommendation": "[GO/CONDITIONAL GO/CAUTION/NO-GO]",
    "components": {
      "disease_association": {"score": [XX], "max": 30},
      "druggability": {"score": [XX], "max": 25},
      "safety": {"score": [XX], "max": 20},
      "clinical_precedent": {"score": [XX], "max": 15},
      "validation_evidence": {"score": [XX], "max": 10}
    }
  },
  "diseases": [...],
  "modality_assessment": {...},
  "safety_flags": [...],
  "recommended_actions": [...]
}
```
```

---

## Section-Specific Guidance

### Executive Summary
**Purpose**: Give reader the key takeaways in 30 seconds

Include:
1. What the target IS (protein class, function)
2. Clinical relevance (disease associations)
3. Druggability status (has drugs? tractable?)
4. One-line recommendation with score

### Section 3: Structural Biology
**Purpose**: Enable structure-based drug design decisions

Must include:
- Total PDB count and best resolution
- Coverage (which domains have structures?)
- AlphaFold availability and confidence
- Complete domain list with positions
- Key binding sites for drug design

### Section 10: Safety Deep Analysis
**Purpose**: Identify safety risks early

Must include:
- Expression in ALL critical tissues (heart, liver, kidney, brain, bone marrow)
- Mouse KO phenotype (if available)
- Known ADRs from approved drugs
- Paralog risks for selectivity

### Section 14: Validation Roadmap
**Purpose**: Provide actionable next steps

Requirements:
- Use priority levels (HIGH/MEDIUM/LOW)
- Each recommendation must be actionable
- Include timeline estimates
- Address identified data gaps

---

## Visualization Requirements

Reports must include ASCII visualizations for key data. These visualizations improve readability and allow quick comprehension of complex data.

### 1. Validation Score Visualization

Display the composite score as a visual radar/bar chart:

```
                    Disease Association (30)
                            |
                            28
                            |
    Safety (20) ----+-------+-------+---- Druggability (25)
                    |       |       |
                    12      |       24
                    |       |       |
            Clinical -------+------- Validation
            Precedent               Evidence
               (15)                  (10)
                 15                    9

    TOTAL SCORE: 88/100 | TIER 1 | GO
```

Alternative horizontal bar format:
```
    Validation Score Breakdown
    ========================================
    Disease Association  [████████████████████] 28/30 (93%)
    Druggability         [███████████████████ ] 24/25 (96%)
    Safety Profile       [████████████        ] 12/20 (60%)
    Clinical Precedent   [████████████████████] 15/15 (100%)
    Validation Evidence  [█████████████████   ]  9/10 (90%)
    ========================================
    TOTAL: 88/100 | TIER 1 | RECOMMENDATION: GO
```

### 2. Tissue Expression Heatmap

Show expression levels across tissues with critical tissue highlighting:

```
    Tissue Expression Profile (TPM)
    ========================================
    Lung          [████████████████████] 120 | Disease-relevant
    Liver         [████████████████    ]  96 | CRITICAL TISSUE
    Kidney        [███████████         ]  68 | CRITICAL TISSUE
    Heart         [████████            ]  48 | CRITICAL TISSUE
    Brain         [████                ]  24 | CRITICAL TISSUE
    Bone Marrow   [██                  ]  12 | CRITICAL TISSUE
    Skin          [████████████        ]  72
    Intestine     [██████              ]  36
    ========================================
    Expression Threshold: Low <20 | Medium 20-50 | High >50 TPM
    Critical Tissues: Heart, Liver, Kidney, Brain, Bone Marrow
```

### 3. Disease Association Bar Chart

Visualize top disease associations:

```
    Top Disease Associations (Open Targets Score)
    ========================================
    NSCLC           [████████████████████] 0.95 | [T1] Approved drugs
    Glioblastoma    [████████████████    ] 0.82 | [T2] Somatic mutations
    Colorectal      [█████████████████   ] 0.71 | [T3] Expression
    Head & Neck     [█████████████       ] 0.55 | [T3] Association
    Ovarian         [██████████          ] 0.42 | [T4] Text-mined
    ========================================
    Score Threshold: Strong >0.7 | Moderate 0.4-0.7 | Weak <0.4
```

### 4. Clinical Development Timeline

Show clinical precedent over time:

```
    Clinical Development Timeline
    ========================================
    2003 |--[Gefitinib]--| FDA Approved (NSCLC)
    2004 |--[Erlotinib]--| FDA Approved (NSCLC)
    2013 |--[Afatinib]---| FDA Approved (NSCLC)
    2015 |--[Osimertinib]| FDA Approved (NSCLC)
    2020 |--[Amivantamab]| FDA Approved (NSCLC)
    ========================================
    Total: 5 FDA-approved drugs | First approval: 2003
```

### 5. Modality Comparison Chart

When multiple modalities assessed:

```
    Modality Tractability Comparison
    ========================================
    Small Molecule    [████████████████████] 92/100 | BEST MATCH
    Antibody          [██████████████████  ] 85/100 |
    PROTAC            [█████████████████   ] 80/100 |
    Gene Therapy      [███████████         ] 55/100 |
    RNA Therapeutic   [███████████████     ] 68/100 |
    Cell Therapy      [██████████████      ] 72/100 |
    ========================================
    Recommended Modality: Small Molecule
```

---

## Interpretation Requirements

Every data section must include interpretation that connects findings to validation decisions. DO NOT simply list data without context.

### Required Interpretation Elements

**1. What the data means**:
- Explain significance of findings
- Compare to benchmark targets
- Identify implications for drug development

**2. How it affects validation**:
- Impact on scoring
- Risk considerations
- Opportunities identified

**3. Recommended actions**:
- Next steps justified by data
- Gaps to address
- Experiments to prioritize

### Example Interpretation Formats

**For Structural Biology Section**:
```markdown
### 3.5 Structural Druggability Assessment

[Data tables...]

**Interpretation**: The availability of 150+ PDB structures with resolutions
better than 2.5A provides a strong foundation for structure-based drug design.
The presence of multiple co-crystal structures with diverse chemotypes
demonstrates tractability and de-risks lead identification. However, the
predominance of ATP-competitive binding modes suggests potential selectivity
challenges across the kinome. The conserved cysteine at position 797 offers
an opportunity for covalent inhibitor development, which could provide
differentiation from existing approved drugs.

**Impact on Validation**: +8 points for structural tractability. The structural
data supports Tier 1 druggability assessment for small molecules.

**Recommendation**: Prioritize type-II or allosteric binding modes for
selectivity; evaluate covalent inhibitor approach for resistant mutations.
```

**For Safety Section**:
```markdown
### 10.4 Safety Liabilities Summary

[Data tables...]

**Interpretation**: The ubiquitous expression pattern across critical tissues
(heart, liver, kidney, brain) presents a significant safety challenge. The
mouse knockout phenotype of embryonic lethality confirms target essentiality,
which may limit therapeutic window. However, the manageable adverse event
profile of approved drugs (rash, diarrhea - primarily on-target) demonstrates
that modulation is feasible with appropriate patient management strategies.

**Impact on Validation**: -8 points for safety profile. The essentiality
concern reduces the safety score to the lower tier. However, clinical
precedent demonstrates manageable toxicity.

**Recommendation**: Implement patient stratification based on predictive
biomarkers; develop targeted delivery approaches to improve therapeutic
index; establish clear safety monitoring protocols.
```

**For Clinical Precedent Section**:
```markdown
### 11.3 Clinical Precedent Score

[Data tables...]

**Interpretation**: With 5 FDA-approved drugs and multiple ongoing clinical
trials, this target has exceptional clinical validation. The timeline from
first approval (2003) to latest approval (2020) shows sustained pharmaceutical
interest. However, this also indicates a crowded competitive landscape that
requires clear differentiation strategy. The focus on NSCLC leaves opportunities
in other approved indications (glioblastoma, colorectal) that are supported
by genetic evidence.

**Impact on Validation**: Maximum 15/15 points for clinical precedent. This
is a Tier 1 validated target by clinical standards.

**Recommendation**: For new programs, consider: (1) next-generation inhibitors
for resistance mutations, (2) combination strategies with immunotherapy,
(3) expansion to other indications with genetic support.
```